{
  "symbol": "MRK",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2558,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.068
  },
  "top_positive": [
    {
      "sent": "Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended June\u00a030, 2025 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) April 1 - April 30 5,233,310 $80.96 5,233,310 $10,813 May 1 - May 31 6,028,900 $78.29 6,028,900 $10,341 June 1 - June 30 5,623,624 $79.14 5,623,624 $9,896 Total 16,885,834 $79.40 16,885,834 (1) Shares purchased during the period were made as part of a plans approved by the Board of Directors in both October 2018 and January 2025, each to purchase up to $10 billion of Merck\u2019s common stock for its treasury.",
      "score": 0.968
    },
    {
      "sent": "Closing of the acquisition is expected in the fourth quarter of 2025, but is subject to certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma\u2019s shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions.",
      "score": 0.9612
    },
    {
      "sent": "Closing of the acquisition is expected in the fourth quarter of 2025, but is subject to certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma\u2019s shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions.",
      "score": 0.9612
    }
  ],
  "top_negative": [
    {
      "sent": "- 42 - Phase 2 Alzheimer\u2019s Disease MK-1167 MK-2214 Cancer MK-1022 (patritumab deruxtecan) (1)(3) Biliary Bladder Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hepatocellular Melanoma Non-Small-Cell lung Ovarian Pancreatic Prostate MK-2400 (ifinatamab deruxtecan) (1) Biliary Bladder Breast Cervical Colorectal Endometrial Head and Neck Hepatocellular Melanoma Non-Small-Cell Lung Ovarian Pancreatic Cancer MK-2870 (sacituzumab tirumotecan) (1)(3) Biliary Bladder Colorectal Neoplasm Malignant Pancreatic MK-3475 Keytruda Prostate MK-3475A (subcutaneous pembrolizumab) Cutaneous Squamous Cell Hematological Malignancies MK-5909 (raludotatug deruxtecan) (1) Biliary Bladder Cervical Colorectal Endometrial Gastric Non-Small-Cell Lung Ovarian Pancreatic Renal Cell Small-Cell Lung MK-6482 Welireg Breast V940 (intismeran autogene) (1)(2) Bladder Renal Cell Eye Disorders MK-8748 HIV-1 Infection MK-8591B (islatravir+ulonivirine) Immunology MK-7240 (tulisokibart) Hidradenitis Suppurativa Systemic Sclerosis Metabolic Dysfunction-Associated Steatohepatitis (MASH) MK-6024 (efinopegdutide) Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(4) Cancer MK-1022 (patritumab deruxtecan) (1) Breast (July 2025) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1084 (2) Colorectal (July 2025) Non-Small-Cell Lung (May 2024) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-2140 (zilovertamab vedotin) Hematological Malignancies (September 2024) MK-2400 (ifinatamab deruxtecan) (1) Esophageal (March 2025) Prostate (May 2025) Small-Cell Lung (July 2024) MK-2870 (sacituzumab tirumotecan) (1)(3) Breast (April 2024) Cervical (July 2024) Endometrial (December 2023) Gastric (May 2024) Non-Small-Cell Lung (November 2023) Ovarian (April 2025) MK-3475 Keytruda Hepatocellular (May 2016) (EU) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-5684 (opevesostat) Prostate (December 2023) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) V940 (intismeran autogene) (1)(2) Melanoma (July 2023) Non-Small-Cell Lung (December 2023) Dengue Fever Virus Vaccine V181 (June 2025) Diabetic Macular Edema MK-3000 (5) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (EU) MK-8591D (islatravir+lenacapavir) (October 2024) (1)(6) HIV-1 Pre-Exposure Prophylaxis MK-8527 (July 2025) Hypercholesterolemia MK-0616 (enlicitide decanoate) (August 2023) Immunology MK-7240 (tulisokibart) Crohn\u2019s Disease (June 2024) Ulcerative Colitis (October 2023) New Molecular Entities Ca ncer MK-3475A ( subcutaneous pembrolizumab ) Previously Approved Solid Tumors (U.S.) Previously Approved Tumors (EU) HIV-1 Infection MK-8591A (doravirine+islatravir) (U.S.) (JPN) Pneumococcal Vaccine Adult V116 Capvaxive (JPN) Respiratory Syncytial Virus MK-1654 Enflonsia (EU) (JPN) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-689) (EU) (JPN) Pulmonary Arterial Hypertension MK-7962 Winrevair (ZENITH) (U.S.) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.8834
    },
    {
      "sent": "JHU answered the complaint in April and May 2023, denying Merck\u2019s claims, and counterclaiming for willful infringement of nine issued U.S.",
      "score": -0.7717
    },
    {
      "sent": "The higher use of cash in financing activities was primarily due to lower proceeds from long-term debt, higher purchases of treasury stock, higher payments on long-term debt, higher dividends paid to shareholders and lower proceeds from the exercise of stock options.",
      "score": -0.765
    }
  ],
  "forward_snippets": [
    "Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction.",
    "The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures.",
    "The guidance is effective for 2025 annual reporting and will result in incremental disclosures within the footnotes to the Company\u2019s financial statements.",
    "In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose addit\nccepted in the United States (U.S.) for complete consolidated financial statements are not included herein.",
    "Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction."
  ],
  "curated_text": "Symbol: MRK. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended June\u00a030, 2025 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) April 1 - April 30 5,233,310 $80.96 5,233,310 $10,813 May 1 - May 31 6,028,900 $78.29 6,028,900 $10,341 June 1 - June 30 5,623,624 $79.14 5,623,624 $9,896 Total 16,885,834 $79.40 16,885,834 (1) Shares purchased during the period were made as part of a plans approved by the Board of Directors in both October 2018 and January 2025, each to purchase up to $10 billion of Merck\u2019s common stock for its treasury. Closing of the acquisition is expected in the fourth quarter of 2025, but is subject to certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma\u2019s shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. Closing of the acquisition is expected in the fourth quarter of 2025, but is subject to certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma\u2019s shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. Top negative sentences: - 42 - Phase 2 Alzheimer\u2019s Disease MK-1167 MK-2214 Cancer MK-1022 (patritumab deruxtecan) (1)(3) Biliary Bladder Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hepatocellular Melanoma Non-Small-Cell lung Ovarian Pancreatic Prostate MK-2400 (ifinatamab deruxtecan) (1) Biliary Bladder Breast Cervical Colorectal Endometrial Head and Neck Hepatocellular Melanoma Non-Small-Cell Lung Ovarian Pancreatic Cancer MK-2870 (sacituzumab tirumotecan) (1)(3) Biliary Bladder Colorectal Neoplasm Malignant Pancreatic MK-3475 Keytruda Prostate MK-3475A (subcutaneous pembrolizumab) Cutaneous Squamous Cell Hematological Malignancies MK-5909 (raludotatug deruxtecan) (1) Biliary Bladder Cervical Colorectal Endometrial Gastric Non-Small-Cell Lung Ovarian Pancreatic Renal Cell Small-Cell Lung MK-6482 Welireg Breast V940 (intismeran autogene) (1)(2) Bladder Renal Cell Eye Disorders MK-8748 HIV-1 Infection MK-8591B (islatravir+ulonivirine) Immunology MK-7240 (tulisokibart) Hidradenitis Suppurativa Systemic Sclerosis Metabolic Dysfunction-Associated Steatohepatitis (MASH) MK-6024 (efinopegdutide) Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(4) Cancer MK-1022 (patritumab deruxtecan) (1) Breast (July 2025) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1084 (2) Colorectal (July 2025) Non-Small-Cell Lung (May 2024) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-2140 (zilovertamab vedotin) Hematological Malignancies (September 2024) MK-2400 (ifinatamab deruxtecan) (1) Esophageal (March 2025) Prostate (May 2025) Small-Cell Lung (July 2024) MK-2870 (sacituzumab tirumotecan) (1)(3) Breast (April 2024) Cervical (July 2024) Endometrial (December 2023) Gastric (May 2024) Non-Small-Cell Lung (November 2023) Ovarian (April 2025) MK-3475 Keytruda Hepatocellular (May 2016) (EU) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-5684 (opevesostat) Prostate (December 2023) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) V940 (intismeran autogene) (1)(2) Melanoma (July 2023) Non-Small-Cell Lung (December 2023) Dengue Fever Virus Vaccine V181 (June 2025) Diabetic Macular Edema MK-3000 (5) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (EU) MK-8591D (islatravir+lenacapavir) (October 2024) (1)(6) HIV-1 Pre-Exposure Prophylaxis MK-8527 (July 2025) Hypercholesterolemia MK-0616 (enlicitide decanoate) (August 2023) Immunology MK-7240 (tulisokibart) Crohn\u2019s Disease (June 2024) Ulcerative Colitis (October 2023) New Molecular Entities Ca ncer MK-3475A ( subcutaneous pembrolizumab ) Previously Approved Solid Tumors (U.S.) Previously Approved Tumors (EU) HIV-1 Infection MK-8591A (doravirine+islatravir) (U.S.) (JPN) Pneumococcal Vaccine Adult V116 Capvaxive (JPN) Respiratory Syncytial Virus MK-1654 Enflonsia (EU) (JPN) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-689) (EU) (JPN) Pulmonary Arterial Hypertension MK-7962 Winrevair (ZENITH) (U.S.) Footnotes: (1) Being developed in a collaboration. JHU answered the complaint in April and May 2023, denying Merck\u2019s claims, and counterclaiming for willful infringement of nine issued U.S. The higher use of cash in financing activities was primarily due to lower proceeds from long-term debt, higher purchases of treasury stock, higher payments on long-term debt, higher dividends paid to shareholders and lower proceeds from the exercise of stock options. Forward-looking snippets: Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting and will result in incremental disclosures within the footnotes to the Company\u2019s financial statements. In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose addit\nccepted in the United States (U.S.) for complete consolidated financial statements are not included herein. Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction."
}